Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting miR-497-5p/PIM1 axis

Qiaojuan Zhu1,2 | Yazhao Li3 | Yang Guo4 | Linjun Hu5 | Zunqiang Xiao1 | Xin Liu2 | Jiahui Wang6 | Qiuran Xu2 | Xiangmin Tong2

1Department of Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
2Key Laboratory of Tumor Molecular Diagnosis and Individualized Medicine of Zhejiang Province, Zhejiang Provincial People’s Hospital (People’s Hospital of Hangzhou Medical College), Hangzhou, China
3Center for Translational Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
4Graduate Department, BengBu Medical College, BengBu, China
5The Medical College of Qingdao University, Qingdao, China
6School of Basic Medical Sciences, Shandong University, Jinan, China

Abstract
The aberrant expression and dysfunction of long non-coding RNAs (lncRNAs) have been identified as critical factors governing the initiation and progression of different human cancers, including diffuse large B-cell lymphoma (DLBCL). LncRNA small nucleolar RNA host gene 16 (SNHG16) has been recognized as a tumour-promoting factor in various types of cancer. However, the biological role of SNHG16 and its underlying mechanism are still unknown in DLBCL. Here we disclosed that SNHG16 was overexpressed in DLBCL tissues and the derived cell lines. SNHG16 knockdown significantly suppressed cell proliferation and cell cycle progression, and it induced apoptosis of DLBCL cells in vitro. Furthermore, silencing of SNHG16 markedly repressed in vivo growth of OCI-LY7 cells. Mechanistically, SNHG16 directly interacted with miR-497-5p by acting as a competing endogenous RNA (ceRNA) and inversely regulated the abundance of miR-497-5p in DLBCL cells. Moreover, the proto-oncogene proviral integration site for Moloney murine leukaemia virus 1 (PIM1) was identified as a novel direct target of miR-497-5p. SNHG16 overexpression rescued miR-497-5p-induced down-regulation of PIM1 in DLBCL cells. Importantly, restoration of PIM1 expression reversed SNHG16 knockdown-induced inhibition of proliferation, G0/G1 phase arrest and apoptosis of OCI-LY7 cells. Our study suggests that the SNHG16/miR-497-5p/PIM1 axis may provide promising therapeutic targets for DLBCL progression.
1 | INTRODUCTION

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin’s lymphoma. Germinal centre B-cell-like (GCB) and activated B-cell-like (ABC) are two major molecular subtypes of DLBCL, which are identified by microarray-based gene expression profiling.\(^1\) NanoString nCounter system,\(^2\) immunohistochemistry\(^3\) and ‘Hans’ classification.\(^4\) The chromosomal translocation caused by Myc, Bcl-2 and/or Bcl-6 structural reorganization is closely related to the therapeutic effect and prognosis of DLBCL.\(^5\) The standard therapeutic process for patients with DLBCL is rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Approximately 60%-70% of DLBCL patients are cured of disease using this approach. However, approximately 30%-40% of patients will relapse.\(^6\) Therefore, it is necessary to better understand the molecular mechanism involved in the initiation and progression of DLBCL and determine new molecular targets as well as therapeutic processes, which will be of great significance for improving the prognosis of DLBCL.

Long non-coding RNAs (lncRNAs), which are defined as RNA sequence >200 nucleotides in length with no or feeble protein-coding potential, are critical regulators of physiological and pathological processes including human cancer.\(^7\) Accumulating studies provide evidence to support the close correlation of the dysregulation of lncRNAs with carcinogenesis, tumour metastasis and therapeutic resistance.\(^8\)-\(^13\) Mechanistically, lncRNAs modulate biological processes via interacting with other cellular macromolecules, including DNA, RNA and protein, at the transcriptional or post-transcriptional level.\(^14\)-\(^16\) Recently, many lncRNAs have been shown to function in cancers by acting as competing endogenous RNAs (ceRNAs), also celebrated as microRNA (miRNA) ‘sponges’ or a miRNA ‘decoy’, which competitively bind to miRNA via the base complementary and thereby increase the abundance of miRNA targets.\(^17\),\(^18\) LncRNA small nucleolar RNA host gene 16 (SNHG16) has been widely investigated in human solid neoplasias.\(^19\)-\(^23\) Functionally, SNHG16 promotes cell proliferation, cell cycle progression, migration, invasion and chemotherapy resistance, and it inhibits apoptosis in most human cancers.\(^19\)-\(^22\) In contrast, SNHG16 functions as a tumour suppressor in acute lymphoblastic leukaemia (ALL) via repressing cell proliferation and invasion by sponging miR-124-3p.\(^24\) Most studies have revealed that SNHG16 functions as a ceRNA to directly interact with miRNAs and, accordingly, regulate their targets.\(^21\),\(^22\),\(^24\) Moreover, SNHG16 acts as an epigenetic regulator to silence p21 and regulates bladder cancer cell proliferation, cell cycle progression and apoptosis.\(^20\)

However, the biological role of SNHG16 and its underlying mechanism in DLBCL are still unknown. SNHG16 acts as a molecular sponge for miR-497-5p to promote the proliferation and invasion of papillary thyroid cancer cells.\(^25\) miR-497-5p is underexpressed in human primary NPM-ALK+ primary lymphoma and inhibits cell cycle progression in cancer cells.\(^26\) Additionally, miR-497-5p functions as a tumour suppressor via targeting the Raf-1-mediated MAPK/ERK pathway in multiple myeloma cells.\(^27\) A previous study has shown that low expression of miR-497-5p indicates poor clinical outcomes in DLBCL patients.\(^28\) Whether SNHG16 exerts a biological function in DLBCL via targeting miR-497-5p has not yet been investigated.

In the present study, the expression pattern of SNHG16 was determined in DLBCL tissues and cell lines. Next, in vitro and in vivo experiments were performed to investigate the biological role of SNHG16 and its potential molecular mechanism in DLBCL.

2 | MATERIALS AND METHODS

2.1 | Patients and tissue samples

A total of forty-eight DLBCL tissues (21 GCB and 27 non-GCB) were collected from patients who underwent surgical resection at Zhejiang Provincial People’s Hospital. There were 29 males and 19 females ranging in age from 19 to 78 years old, with a median age of 56 years. All enrolled DLBCL patients had not been previously treated and signed an informed consent to participate in this study. All tumour samples were pathologically confirmed as DLBCL according to the 2008 WHO classification.\(^29\) Fourteen samples of reactive lymph node hyperplasia (RLH) tissues served as controls. There were eight males and six females ranging in age from 22 to 75 years old, with a median age of 55 years. There was no significant difference in age and sex ratio between the DLBCL group and RLH group. This study was approved by the Ethics Committee of Zhejiang Provincial People’s Hospital.

2.2 | Cell culture

The GCB subtype cell line OCI-LY7 and ABC subtype cell line OCI-LY3 were obtained from the ATCC. OCI-LY7 and OCI-LY3 cells were incubated in complete Iscove’s modified essential medium (IMDM; Gibco) supplemented with 10% foetal bovine serum (FBS; Gibco). HEK293T cells were maintained in our laboratory and cultured under standard conditions. The cell culture medium was supplemented with 1% penicillin/streptomycin (Invitrogen). Cell culture was performed at 37°C in an atmosphere containing 5% CO\(_2\). Normal B lymphocytes were negatively selected from the peripheral blood of a 34-year-old healthy female using an immunomagnetic technique (Human B Cell Enrichment Kit, Stem Cell Technologies).

2.3 | Transfection and lentiviral vector infection

miR-497-5p mimics, miR-497-5p inhibitors (anti-miR-497-5p) and control clones were purchased from RiboBio. The cDNA encoding
SNHG16 was PCR-amplified by the Pfu Ultra II Fusion HS DNA Polymerase (Stratagene, Agilent Technologies), and the full-length proviral integration site for the Moloney murine leukaemia virus 1 (PIM-1) ORF was obtained from human mRNA by reverse transcription-PCR (RT-PCR). The clone sequences were controlled for artificial point mutations and inserted into pcDNA3.1 (Invitrogen). These plasmids were transfected into cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. The lentivector-mediated SNHG16 shRNAs (SNHG16 shRNA-1 and SNHG16 shRNA-2) and non-targeting (NT) shRNA were obtained from RiboBio. Polybrene (8 μg/mL; Sigma-Aldrich) was added to the culture medium to increase the efficiency of infection.

### 2.4 Western blot analysis

Total protein was extracted using RIPA lysis buffer (Beyotime). A BCA kit (Pierce) was used to measure the protein concentration. Equal amounts of protein samples (20 μg) were subjected to 10% SDS-PAGE and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore). The membranes were incubated with primary antibodies, which were diluted in 5% TBST skimmed milk, overnight at 4°C and subsequently incubated with horseradish peroxidase (HRP)-conjugated antiserum or anti-rabbit IgG at room temperature for 1-2 h. Then, the membranes were visualized with ECL reagents (Millipore) and imaged using an Amersham Imager 600 from GE Healthcare Life Sciences. PIM1 antibody (sc-13513), proliferating cell nuclear antigen (PCNA) antibody (sc-25280), Bcl-2 antibody (sc-7382) and β-actin antibody (sc-8432) were purchased from Santa Cruz Biotechnology.

### 2.5 RNA extraction and quantitative real-time PCR (qRT-PCR)

Total RNA was extracted using TRizol reagent (Invitrogen) according to the manufacturer’s procedure and reverse-transcribed into cDNA using a PrimeScript reverse transcriptase reagent kit (Takara) or TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems) according to the manufacturer’s instructions. Next, qRT-PCR was conducted with the Applied Biosystems 7500 Sequence Detection system using a miRNA-specific TaqMan miRNA Assay Kit (Applied Biosystems) and the SYBR Premix Ex Taq™ Kit (Takara). The primers are listed in Table 1.

### 2.6 Cell proliferation and flow cytometry analysis

Cell proliferation was detected via the CCK-8 (Cell Counting Kit-8, Dojindo) assay as previously described. The cell cycle distribution and apoptosis were measured using a FACSCanto II flow cytometer (BD Biosciences). PI/RNase Staining Buffer (BD Biosciences) and the PE Annexin V Apoptosis Detection Kit I (BD Biosciences) were used for these assays as previously described.

### 2.7 In vivo tumour xenograft experiments

The animal studies were approved by the Institutional Animal Care and Use Committee of Xi’an Jiaotong University, Xi’an, China. Eight male NOD/SCID mice (6-8 weeks old) were raised in an SPF environment in the animal facility during the experimental procedures. Briefly, low-passage 5 × 10⁶ OCI-LY7 cells with or without SNHG16 knockdown that were suspended in 100 μL PBS were subcutaneously injected into the left flank of mice. Tumour volumes were monitored every 3 days after tumour appearance using an electronic digital caliper. The tumour volume was calculated as follows: (smallest diameter² × largest diameter)/2. After 3 weeks, the mice were killed, and the xenograft tumour tissues were analysed by qRT-PCR and immunoblotting for SNHG16, PCNA and Bcl-2 expression.

### 2.8 Luciferase reporter assay

The pEZX-MT06 luciferase reporter vector containing the 3’UTR of PIM1 was obtained from GeneCopoeia Inc. The synthetic SNHG16 fragment was subcloned into the pGL3 luciferase reporter vector.

**TABLE 1** Primers used in qRT-PCR analysis

| Name       | Sequence (5′ → 3′)                      |
|------------|----------------------------------------|
| miR-497-5p | RT primer: GTCGTATCCAGTGCGAGGTGT/CGACAGTTT |
|            | Forward: GTGCAGGGTTCGAGTATT             |
|            | Reverse: TACGCTGCGACACGCTTGTG          |
| U6         | RT primer: GAACGCCTTCGGAATTTGAGCAT     |
|            | Forward: CTCGCTTCGAGCAGCACA            |
|            | Reverse: AACGCTTCGAAATTTCG             |
| SNHG16     | Forward: CCAAGCTTTCCGGAATTTCG          |
|            | Reverse: CGGGATTTTGACGGTTAGTTTTCCCCAG  |
| PIM1       | Forward: GAGAAAGACCGGATTCGCCG          |
|            | Reverse: CAGTCCAGGAGCTAAGG            |
| GAPDH      | Forward: AGGTCTGGTGAAGCGATTG           |
|            | Reverse: TGAGACCATTGTAGTGGTCG          |

2.6 | Cell proliferation and flow cytometry analysis

Cell proliferation was detected via the CCK-8 (Cell Counting Kit-8, Dojindo) assay as previously described. The cell cycle distribution and apoptosis were measured using a FACSCanto II flow cytometer (BD Biosciences). PI/RNase Staining Buffer (BD Biosciences) and the PE Annexin V Apoptosis Detection Kit I (BD Biosciences) were used for these assays as previously described.

2.7 | In vivo tumour xenograft experiments

The animal studies were approved by the Institutional Animal Care and Use Committee of Xi’an Jiaotong University, Xi’an, China. Eight male NOD/SCID mice (6-8 weeks old) were raised in an SPF environment in the animal facility during the experimental procedures. Briefly, low-passage 5 × 10⁶ OCI-LY7 cells with or without SNHG16 knockdown that were suspended in 100 μL PBS were subcutaneously injected into the left flank of mice. Tumour volumes were monitored every 3 days after tumour appearance using an electronic digital caliper. The tumour volume was calculated as follows: (smallest diameter² × largest diameter)/2. After 3 weeks, the mice were killed, and the xenograft tumour tissues were analysed by qRT-PCR and immunoblotting for SNHG16, PCNA and Bcl-2 expression.

2.8 | Luciferase reporter assay

The pEZX-MT06 luciferase reporter vector containing the 3’UTR of PIM1 was obtained from GeneCopoeia Inc. The synthetic SNHG16 fragment was subcloned into the pGL3 luciferase reporter vector.
ZHU et al. (Promega). The potential binding sites of miR-497-5p in the 3′UTR of PIM1 and SNHG16 were mutated using a Quick-change site-directed mutagenesis kit (Agilent Technologies). HEK293T cells were cotransfected with different luciferase reporter vectors and miR-497-5p mimics or inhibitors. Forty-eight hours after transfection, luciferase activity was measured with the dual-luciferase assay system (Promega).

2.9 | Pull-down assay with biotinylated miR-497-5p

OCI-LY7 cells were transduced with biotin-labelled wild-type (wt) miR-497-5p and mutated (mt) miR-497-5p plasmids (RiboBio), respectively. Forty-eight hours after transfection, cells were harvested and incubated with a specific lysate buffer (Ambion) for 10 minutes. Then, the cell lysates were mixed with M-280 streptavidin magnetic beads (Sigma) for 3 hours at 4°C. A biotin-labelled antagonistic miR-497-5p probe was used as a negative control (Bio-NC). The pull-down products were subjected to qRT-PCR to evaluate SNHG16 expression.

2.10 | Statistical analysis

Data analysis was performed using GraphPad Prism 6.0 Software (GraphPad Inc). All data are presented as the mean ± SD. Differences between groups were analysed by Student’s t test or ANOVA. The correlation analysis was performed by Pearson’s correlation test. P < .05 was considered to indicate statistical significance.

3 | RESULTS

3.1 | SNHG16 is overexpressed in DLBCL

We detected the expression of SNHG16 in DLBCL tissues and RLH tissues using qRT-PCR. As shown in Figure 1A, the expression of SNHG16 was significantly up-regulated in DLBCL compared with RLH tissues (P = .0004). Moreover, DLBCL tissues from patients with advanced tumour stages showed prominently higher levels of SNHG16 compared with those from patients with early tumour stages (P < .0001, Figure 1B). Next, we further determined the levels of SNHG16 in B lymphocytes and DLBCL cell lines. Consistently, the expression of SNHG16 in both OCI-LY7 and OCI-LY3 cells was prominently higher than that in B lymphocytes (P < .05, Figure 1C). Thus, SNHG16 was highly expressed in DLBCL.

3.2 | SNHG16 regulates DLBCL cell proliferation, cell cycle progression and apoptosis

As SNHG16 was aberrantly overexpressed in DLBCL, we further investigated its biological role. We markedly down-regulated SNHG16 expression by transfecting different shRNAs into two DLBCL cell lines, OCI-LY7 and OCI-LY3 cells (P < .05, Figure 2A). The CCK-8 assay showed that SNHG16 knockdown prominently reduced the proliferation of DLBCL cells (P < .05, Figure 2B). Additionally, knockdown of SNHG16 led to cell cycle arrest at G0/G1 phase in both OCI-LY7 and OCI-LY3 cells (P < .05, Figure 2C). Furthermore, the portion of apoptotic DLBCL cells was obviously increased by SNHG16 knockdown (P < .05, Figure 2D). Taken together, SNHG16 knockdown inhibited cell proliferation and cell cycle progression, and it induced apoptosis of DLBCL cells.

3.3 | Knockdown of SNHG16 suppresses in vivo growth of DLBCL cells

Next, the oncogenic role of SNHG16 was further confirmed in vivo. OCI-LY7 cells with or without SNHG16 were subcutaneously injected into mice. Tumour growth curves suggested that SNHG16 knockdown markedly inhibited in vivo tumour growth of OCI-LY7 cells (P < .05, Figure 3A). The expression of SNHG16 in xenograft tumour tissues collected from the SNHG16 knockdown group was significantly lower than in the control group (P < .05, Figure 3B). Moreover, immunoblotting analysis was performed to detect the levels of the proliferation (PCNA) marker and anti-apoptosis marker (Bcl-2) in xenograft tumour tissues. Accordingly, the levels of PCNA and Bcl-2 were significantly lower in xenograft tumour tissues collected from the SNHG16 knockdown than the control group (P < .05, Figure 3C). Altogether, SNHG16 exerted a tumour-promoting role in DLBCL.
3.4 | SNHG16 functions as a ceRNA by interacting with miR-497-5p

Subsequently, we attempted to investigate the molecular mechanism involved in the biological role of SNHG16 in DLBCL. According to the starBase V3.0 online platform, more than a dozen candidate target miRNAs for SNHG16 were predicted. Only miR-497-5p was previously indicated as a candidate tumour suppressor in DLBCL and inversely correlated with SNHG16 level in DLBCL samples from the TCGA database ($r = -0.422, P = .0031$, Figure S1A). qRT-PCR data
revealed that miR-497-5p expression in DLBCL tissues was significantly lower than in RLH tissues \( (P = .0025, \text{Figure 4A}) \). Moreover, an inverse correlation was observed between SNHG16 and miR-497-5p expression in both DLBCL and RLH tissues \( (P < .05, \text{Figure 4B and Figure S1B}) \). Next, SNHG16 knockdown marked increased levels of miR-497-5p in both OCI-LY7 and OCI-LY3 cells \( (P < .05, \text{Figure 4C}) \). As shown in Figure 4D, miR-497-5p overexpression decreased the luciferase activity of vectors containing wt SNHG16 \( (P < .05) \), whereas the fluorescence intensity of vectors containing mt SNHG16 was not changed after miR-497-5p overexpression. Moreover, SNHG16 was obviously pulled down by biotinylated wt miR-497-5p \( (P < .05, \text{Figure 4E}) \). However, mutagenesis of the binding sites between SNHG16 and miR-497-5p abolished this interaction (Figure 4E). Thus, the above results indicated that SNHG16 directly interacted with miR-497-5p and regulated its abundance in DLBCL cells.

3.5 | PIM1 is a direct target of miR-497-5p

The starBase V3.0 platform suggested dozens of targets for miR-497-5p. The proto-oncogene PIM1, which was negatively correlated with miR-497-5p expression in DLBCL tissues \( (r = -.543, P < .0001, \text{Figure S1C}) \) and acted as an oncogene in DLBCL,\(^23\) was predicted as a candidate target of miR-497-5p. The qRT-PCR data revealed significantly elevated expression of PIM1 mRNA in DLBCL tissues than in RLH tissues \( (P = .0008, \text{Figure 5A}) \). Moreover, an inverse correlation between PIM1 mRNA and miR-497-5p expression was observed in both DLBCL and RLH tissues \( (P < .05, \text{Figure 5B and Figure S1D}) \). Notably, miR-497-5p overexpression markedly reduced the levels of PIM1 protein, whereas miR-497-5p knockdown prominently led to increased expression of PIM1 protein in both OCI-LY7 and OCI-LY3 cells \( (P < .05, \text{Figure S1C}) \). Importantly, miR-497-5p overexpression reduced whereas miR-497-5p knockdown increased the fluorescence intensity of vectors containing the wt 3’UTR of PIM1 \( (P < .05, \text{Figure 5E}) \). However, modulation of the miR-497-5p level had no significant impact on the luciferase activity of vectors containing the mt 3’UTR of PIM1 (Figure 5E). Interestingly, SNHG16 overexpression rescued miR-497-5p-induced down-regulation of PIM1 in both OCI-LY7 and OCI-LY3 cells \( (P < .05, \text{Figure 5F}) \). Thus, SNHG16 functioned as a ceRNA to sponge miR-497-5p and subsequently regulate PIM1 expression.

3.6 | PIM1 restoration reverses SNHG16 knockdown-attenuated DLBCL cell growth

Rescue experiments were performed to disclose whether PIM1 was a downstream effector of SNHG16 in DLBCL cells. The expression of PIM1 was restored by transfecting expression plasmid into OCI-LY7 cells with SNHG16 knockdown \( (P < .05, \text{Figure 6A}) \). PIM1 restoration rescued SNHG16 knockdown-induced inhibition of proliferation and G0/G1 phase arrest in OCI-LY7 cells \( (P < .05, \text{Figure 6B,C}) \).
Furthermore, PIM1 overexpression reduced apoptosis of OCI-LY7 cells with SNHG16 knockdown (P < .05, Figure 6D). Taken together, SNHG16 functioned as an oncogene by targeting the miR-497-5p/PIM1 axis in DLBCL cells.

4 | DISCUSSION

Previous studies have reported the aberrant expression of lncRNAs in DLBCL. However, the expression pattern of SNHG16 in DLBCL has remained unexplored. In the present study, we found that increased expression of SNHG16 was a frequent event in DLBCL. Consistently, up-regulated expression of SNHG16 was detected in DLBCL cells compared with normal B lymphocytes. SNHG16 is overexpressed in various types of human cancers. Moreover, increased expression of SNHG16 independently predicts a poor prognosis of patients with NSCLC and bladder cancer.

In addition, serum SNHG16 expression is suggested as a potential early diagnostic biomarker for lung cancer. Here we found that DLBCL tissues from patients with advanced tumour stages showed prominent higher levels of SNHG16 compared with those from patients with early tumour stages. Several studies have revealed the mechanism involved in the deregulation of SNHG16 in human cancer. In CRC cells, inactivation of Wnt signalling leads to decreased expression of SNHG16. The proto-oncogene c-Myc is identified as an upstream regulator of SNHG16 in OSCC. Moreover, upstream transcription factor 1 (USF1) positively regulates the expression of SNHG16 by directly binding to the promoter region of SNHG16 in glioma cells. Therefore, the collection of more DLBCL samples is merited to investigate the diagnostic and prognostic potential of SNHG16, as well as to further explore the potential mechanism underlying the overexpression of SNHG16 in DLBCL.

Recent studies have demonstrated that lncRNAs function as oncogenes or tumour suppressors in DLBCL. For instance, lncRNA...
SMAD5-AS1 plays a tumour suppressive role in DLBCL by inhibiting cell proliferation in vitro and repressing tumour growth in vivo.\textsuperscript{39} LncRNA PANDA leads to cell cycle arrest at G0/G1 phase in DLBCL cells.\textsuperscript{40} Conversely, lncRNA MALAT-1 contributes to proliferation and cell cycle progression, and it represses apoptosis of DLBCL cells.\textsuperscript{41} Additionally, IncRNA HULC has a tumour-promoting role in DLBCL.\textsuperscript{35} In this study, SNHG16 knockdown-induced inhibition of proliferation, G0/G1 phase arrest and apoptosis of OCI-LY3 and OCI-LY7 cells, and it suppressed in vivo tumour growth of OCI-LY7 cells. These results suggested that SNHG16 could facilitate DLBCL progression by regulating cell proliferation, cell cycle progression and apoptosis. However, an artificial model was employed in this study, thus providing only an idea about the underlying mechanism and necessitating further studies. SNHG16 has been identified as a ceRNA in other tumour models.\textsuperscript{21,38,42} Thus, we further investigated the candidate target miRNAs for SNHG16 in DLBCL based on an online platform. The luciferase reporter assay in HEK293T cells and RNA pull-down assay in DLBCL cells demonstrated that SNHG16 acted as a ceRNA by directly interacting with miR-497-5p and inversely regulated its abundance in DLBCL cells. miR-497-5p was underexpressed and negatively correlated with SNHG16 expression in DLBCL tissues. A previous study has found that low
ZHU ET AL.

expression of miR-497-5p indicates poor clinical outcomes in DLBCL patients,\textsuperscript{28} which is consistent with the tumour suppressive potential of miR-497-5p in our study. In addition, the luciferase reporter assay in HEK293T cells indicated that miR-497-5p functioned as a post-transcriptional regulator of PIM1 by directly binding to the 3′UTR. PIM1 was highly expressed in DLBCL and inversely correlated with miR-497-5p expression. A previous study has demonstrated that overexpression of PIM1 is correlated with poor clinical outcomes of DLBCL patients.\textsuperscript{32} Functionally, PIM1 contributes to cell proliferation in vitro and tumour growth in vivo, indicating a potential therapeutic target in DLBCL.\textsuperscript{33,43} Interestingly, SNHG16 overexpression rescued miR-497-5p-induced repression of PIM1. Accordingly, the restoration of PIM1 expression abolished SNHG16 knockdown-induced cell proliferation inhibition, cell cycle arrest and apoptosis of DLBCL cells. Thus, our data revealed that SNHG16 facilitated tumour growth of DLBCL by targeting the miR-497-5p/PIM1 axis.

In summary, these results provide new insights into the tumour-promoting role of the SNHG16/miR-497-5p/PIM1 axis in DLBCL progression, which may improve our understanding of the pathogenesis of DLBCL and provide potential therapeutic targets.

5 | CONCLUSIONS

To conclude, we have found that lncRNA SNHG16 is highly expressed in DLBCL. Knockdown of SNHG16 inhibits DLBCL cell proliferation, suppresses cell cycle progression and induces apoptosis in vitro and in vivo. Mechanistically, SNHG16 functions as a ceRNA by directly interacting with miR-497-5p. PIM1 is a novel downstream target of miR-497-5p and mediates the tumour-promoting role of the SNHG16/miR-497-5p axis in DLBCL cells. Our results support the notion that the SNHG16/miR-497-5p/PIM1 axis may provide novel potential targets for DLBCL therapy.

ACKNOWLEDGEMENT

This study was supported by grants from the National Science and Technology Major Project for New Drug (No. 2017ZX301033); the National Natural Science Foundation of China (81874049, 81602179, 81570198); the Co-construction of Provincial and Department Project (WKJ-ZJ-1919); the Zhejiang Provincial Natural Science Foundation of China (LY19H160036).

CONFLICT OF INTEREST

All authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

Qiuran Xu and Xiangmin Tong conceived and designed the experiments; Qiaojuan Zhu, Yazhao Li, Yang Guo, Linjun Hu, Zunqiang Xiao, and Xin Liu performed the experiments; Qiaojuan Zhu, Yazhao Li and Yang Guo analysed the data; Jiahui Wang contributed reagents/
materials/analysis tools; Qiaojuan Zhu and Qiuran Xu wrote the paper. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Qiuran Xu https://orcid.org/0000-0003-2171-9279
Xiangmin Tong https://orcid.org/0000-0002-4175-0321

REFERENCES

1. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
2. Veldman-Jones MH, Lai Z, Wappett M, et al. Reproducible, quantitative, and flexible molecular subtyping of clinical DLBCL samples using the NanoString nCounter System. Clin Cancer Res. 2015;21:2367-2378.
3. Coutinho R, Clear AJ, Owen A, et al. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin Cancer Res. 2013;19:6686-6695.
4. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282.
5. Nosrati A, Monabati A, Sadeghipour A, Radmanesh F, Safaei A, Movahedinia S. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type. Ann Hematol. 2019;98:169-173.
6. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50:74-87.
7. Lorenzi L, Avila Cobos F, Decock A, et al. Long noncoding RNA expression profiling in cancer: challenges and opportunities. Genes Chromosomes Cancer. 2019;58:191-199.
8. Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77:3965-3981.
9. Yan H, Bu P. Non-coding RNAs in cancer stem cells. Cancer Lett. 2018;421:121-126.
10. Tu K, Dong Q, Tao J. Role of ncRNAs in hepatocellular carcinoma. Biomed Res Int. 2018;2018:3014543.
11. Zhang L, Wang L, Wang Y, et al. lncRNA KTN1-AS1 promotes tumor growth of hepatocellular carcinoma by targeting miR-23c/ERBB2IP axis. Biomed Pharmacother. 2019;109:1140-1147.
12. Wang Y, Liu Z, Yao B, et al. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis. Mol Cancer. 2017;16:123.
13. Wang Y, Yang L, Chen T, et al. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. Mol Cancer. 2019;18:28.
14. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452-463.
15. Wang Y, Sun L, Wang L, et al. Long non-coding RNA DSCR15 acts as a molecular sponge for miR-485-5p to activate Wnt/beta-catenin signal pathway in hepatocellular carcinoma. Cell Death Dis. 2018;9:851.
36. Li S, Zhang S, Chen J. c-Myc induced upregulation of long non-coding RNA SNHG16 enhances progression and carcinogenesis in oral squamous cell carcinoma. Cancer Gene Ther. 2019; https://doi.org/10.1038/s41417-018-0072-8. [Epub ahead of print]
37. Zhu H, Zhang L, Yan S, et al. LncRNA16 is a potential biomarker for diagnosis of early-stage lung cancer that promotes cell proliferation by regulating the cell cycle. Oncotarget. 2017;8:7867-7877.
38. Wang D, Zheng J, Liu X, et al. Knockdown of USF1 inhibits the vasculogenic mimicry of glioma cells via stimulating SNHG16/miR-212-3p and linc00667/miR-429 Axis. Mol Ther Nucleic Acids. 2019;14:465-482.
39. Zhao CC, Jiao Y, Zhang YY, et al. Lnc SMAD5-AS1 as ceRNA inhibit proliferation of diffuse large B cell lymphoma via Wnt/beta-catenin pathway by sponging miR-135b-5p to elevate expression of APC. Cell Death Dis. 2019;10:252.
40. Wang Y, Zhang M, Xu H, et al. Discovery and validation of the tumor-suppressive function of long noncoding RNA PANDA in human diffuse large B-cell lymphoma through the inactivation of MAPK/ERK signaling pathway. Oncotarget. 2017;8:72182-72196.
41. Li LJ, Chai Y, Guo XJ, Chu SL, Zhang LS. The effects of the long non-coding RNA MALAT-1 regulated autophagy-related signaling pathway on chemotherapy resistance in diffuse large B-cell lymphoma. Biomed Pharmacother. 2017;89:939-948.
42. Wang X, Hu K, Chao Y, Wang L. LncRNA SNHG16 promotes proliferation, migration and invasion of osteosarcoma cells by targeting miR-1301/BCL9 axis. Biomed Pharmacother. 2019;114:108798.
43. Kuo HP, Ezell SA, Hsieh S, et al. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. Am J Cancer Res. 2016;6:2489-2501.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Zhu Q, Li Y, Guo Y, et al. Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting miR-497-5p/PIM1 axis. J Cell Mol Med. 2019;23:7395–7405. https://doi.org/10.1111/jcmm.14601